A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Since the beginning of the COVID-19 pandemic, there have been efforts by scientists, governments, and others to determine the origin of the SARS-CoV-2 virus. Similar to other outbreaks, the virus was derived from a bat-borne virus and most likely was transmitted to humans via another animal in nature, or during wildlife bushmeat trade such as that in food markets. While other explanations, such as SARS-CoV-2 being accidentally released from a laboratory, have been proposed, they are not supported by evidence. Conspiracy theories about the virus's origin have proliferated widely. Research is ongoing as to whether SARS-CoV-2 came directly from bats or indirectly through an intermediate host, such as pangolins, civets, or raccoon dogs. Genomic sequence evidence indicates the spillover event introducing SARS-CoV-2 to humans likely occurred in late 2019. As with the 2002–2004 SARS-CoV-1 outbreak, efforts to trace the specific geographic and taxonomic origins of SARS-CoV-2 could take years, and results may be inconclusive. In July 2022, two papers published in Science described novel epidemiological and genetic evidence that suggested the pandemic likely began at the Huanan Seafood Wholesale Market and did not come from a laboratory. In 2026, virologist Joel Wertheim and colleagues at UCSD published a study in Cell that compared evolutionary patterns of outbreaks of Ebola, influenza and other viruses. They found that the mutation pattern of SARS-CoV-2 matched five naturally occurring outbreaks, but did not resemble the 1977 Russian flu outbreak which was likely from a lab leak.
=== Curtailment of emergency executive powers === Congress enacted the IEEPA in 1977 to clarify and restrict presidential power during times of declared national emergency under the Trading with the Enemy Act of 1917 ("TWEA"). Under TWEA, starting with Franklin D. Roosevelt in 1933, presidents had the power to declare emergencies without limiting their scope or duration, without citing the relevant statutes, and without congressional oversight. The Supreme Court in Youngstown Sheet & Tube Co. v. Sawyer limited what a president could do in such an emergency, but did not limit the emergency declaration power itself. A 1973 Senate investigation found (in Senate Report 93-549) that four declared emergencies remained in effect: the 1933 banking crisis with respect to the hoarding of gold, a 1950 emergency with respect to the Korean War, a 1970 emergency regarding the postal workers strike, and a 1971 emergency in response to the government's deteriorating economic and fiscal conditions. Congress terminated these emergencies with the National Emergencies Act, and then passed the IEEPA to restore the emergency power in a limited, overseeable form. Unlike TWEA, IEEPA was drafted to permit presidential emergency declarations only in response to threats originating outside the United States. Beginning with Jimmy Carter in response to the Iran Hostage Crisis, presidents have invoked IEEPA to safeguard U.S. national security interests by freezing or "blocking" assets of belligerent foreign governments, or certain foreign nationals abroad.
=== Entomotherapy: Nutritional and Medicinal Benefits === Insects have played a significant role in traditional and modern medicine across various cultures. The Food and Agriculture Organization (FAO) Edible Insects Report highlights the nutritional and therapeutic potential of insects, they have high protein content, essential fatty acids, and bioactive compounds. Some traditional healing practices incorporate insects as remedies for inflammatory conditions, infections, and gastrointestinal disorders. In China and other parts of Asia silkworm derived compounds have been used in traditional medicine to treat high blood pressure and atherosclerosis. Similarly termites and grasshoppers are utilized in African medicine for their perceived immune boosting effects.
According to a 2011 USDA Foreign Agricultural Service report, most of the clientele of traditional open-air markets in Nigeria are low and middle income consumers. From 2008 to 2009, a group of food safety researchers launched an initiative working with a small group of butchers in the fresh food section of Bodija Market in Ibadan to promote positive food safety practices and peer-to-peer training. The initiative led to 20% more meat samples being of acceptable quality. A follow-up study in 2019 on the same group of butchers found that, while many of the butchers still remembered the food safety practices, "none of the butchers reported that they continued to buy and replace the materials after the exhaustion of those distributed during the intervention programme". The follow-up study found that the microbiological sanitation in 2018 was even worse than before the 2008–2009 intervention. In 2014, the license of the slaughterhouse in the fresh food section of Bodija Market was revoked due to unhygienic meat handling practices. In its place, the local government opened the Ibadan Central Abattoir in Amosun Village, Akinyele through public-private partnerships. The new facility is equipped with modern facilities for slaughter and processing of meat were provided in 2014 through public-private partnerships and is one of the largest abattoirs in West Africa, consisting of 15 hectares of land with stalls for 1000 meat sellers, 170 shops, administrative building, clinic, canteen, cold room, and an incinerator.
Sources: en.wikipedia.org
== History == The sucrose hemolysis test was developed in the 1960s. Hartmann and Jenkins first described the test in 1966. The test was devised as a superior screen for PNH compared to the Ham's acid hemolysis test (HT) that was developed in the 1930s. For decades, these two tests were the primary methods of diagnosing PNH. The test is now obsolete being replaced by more advanced methods such as flow cytometry with monoclonal antibodies CD55/CD59 that target glycosylphosphatidylinositol-anchored proteins (GPI-AP) with the addition of inactivated fluorescently labeled bacterial toxins, such as fluorescently labeled aerolysin (FLAER). Flow cytometry is the most sensitive and useful assay currently available to screen and diagnosis PNH.
== American Society for Mass Spectrometry == The major awards from the American Society for Mass Spectrometry are John B. Fenn Award for a Distinguished Contribution in Mass Spectrometry, Biemann Medal, Fellows of ASMS, Research Award, Research at Primarily Undergraduate Institutions (PUIs) Award, Al Yergey Mass Spectrometry Scientist Award, Ron Hites Award, and Diversity, Equity, Inclusion, and Accessibility Mentorship Award. A number of notable women mass spectrometrists served as presidents of the American Society for Mass Spectrometry.
Commission C1: Cryobiology, Cryomedicine and Health Products Commission C1 Cryobiology, Cryomedicine and Health Products have clearly defined objectives in cryobiology, cryomedicine and health products research; knowledge dissemination; technology transfer and education. This commission participates in the various workshop series on cryoprocessing of biopharmaceuticals and biomaterials, as well as establishing training actions concerning the commission's multidisciplinary and interdisciplinary needs, including for the following commissions: A1 Cryophysics, Cryoengineering, A2 Liquefaction and Separation of Gases, and C1 Cryobiology, Cyomedicine and Health Products.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.